by Richard O. Snyder et al.
Volume 7, Issue 2 (Summer 2008)
Recombinant adeno-associated viral (rAAV) vectors have proven to be efficient vehicles for gene transfer in animal models. The attractive features of this vector system are long-term gene expression with little or no associated toxicities following administration to a variety of tissues. Previous and ongoing clinical trials in humans demonstrate a very good over-all safety profile. However, one of the caveats of this work that has been carried out by several laboratories is the inability to normalize vector doses administered by different investigators to animals and humans. Most of the work to date has involved AAV serotype2 vectors, but vector systems based on other AAV serotypes are being rapidly developed…
Citation:
Snyder RO et al. Manufacture and Stability of the Recombinant Adeno-Associated Virus Serotype 2 Vector Reference Standard. BioProcess J, 2008; 7(2): 8-14. http://dx.doi.org/10.12665/J72.Snyder